Whilst the therapeutic potential of BDNF has been illustrated in preclinical stroke models [27–29], clinical success has been challenged by poor blood-brain barrier (BBB) permeability, short half-life, and off-target effects. The gene discussed is BDNF; the disease is Stroke.